STIFEL 2026 HEALTHCARE CONFERENCE - OVID THERAPEUTICS INC

Financial Performance:

• The company currently holds sufficient cash runway extending to 2029.
• No specific revenue, earnings, profit margin, or debt figures were disclosed, consistent with a pre-revenue biopharmaceutical company in clinical development.
• Safety data from Phase 1 studies for OV329 involving ~100 human subjects indicates a clean tolerability profile.

Guidance and Future Outlook:

• Key Catalysts: Management forecasts 4–5 major data readouts or "card turnovers" within the next 6–12 months.
• Phase 1 (OV4071): Expected to read out in Q1 of next year; includes a "ketamine challenge" translational study to assess mechanism and predictive clinical effects.
• Phase 2 (OV329): A 12-week, registrational-quality Phase 2 study in focal epilepsy is currently running and expected to read out in the second half of next year.
• Pediatric Programs: A Phase 2 open-label study for Tuberous Sclerosis Complex (TSC) seizures is initiating this year.
• Strategic Goal: Position Ovid as the definitive leader in KCC2 activation within the next two years.
• Future Indications: Following successful schizophrenia proof-of-concept (PoC) data (anticipated mid-next year), the pipeline aims to expand to other neurodegenerative psychoses (Alzheimer's, Parkinson's) and bipolar mania.

Business Segments and Product Lines:

• OV4071 (KCC2 Direct Activator): An oral small molecule targeting the KCC2 chloride transporter to normalize GABA function.
  • Current Status: Phase 1 clinical trial ongoing; showing potent, consistent neuroactivity in >40 animal models.
  • Mechanism: Uniquely modulates neural hyperexcitability with a "self-limiting" safety profile (prevents over-modulation) and no significant sedation.
  • Preclinical Efficacy: Demonstrates profound rescue of positive symptoms, negative symptoms, and cognitive deficits in psychosis models, outperforming or matching reference drugs like risperidone and clozapine.
• OV329 (GABA-Aminotransferase Inhibitor): A validated anticonvulsant mechanism designed to inhibit the enzyme degrading GABA.
  • Differentiation: Solves the retinal toxicity (Vigabatrin/Vigabatin) associated with first-generation drugs by avoiding specific partitioning and secondary enzyme inhibition.
  • Dosing: Designed for once-daily administration without titration or significant drug-drug interactions.
  • Pipeline: Includes adult focal epilepsies and severe pediatric epileptic encephalopathies (specifically Infantile Spasms and Tuberous Sclerosis Complex).
  • Safety: Preclinical and Phase 1 data suggest improved safety over Vigabatrin with no evidence of irreversible vision loss.

Market and Competitive Landscape:

• Schizophrenia/Psychosis: Ovid identifies a critical unmet need for non-sedating treatments that improve cognition and negative symptoms; the recent FDA approval of CoBENFi is viewed as validation of the mechanism class, with Ovid aiming for a potential "five to six times" more effective profile.
• Epilepsy: The market lacks a drug with a new mechanism of action that is safe, effective, and easy to use; current competitors face tolerability and interaction issues.
• Target Uniqueness: KCC2 is a "master switch" for neural hyperexcitability expressed only in the CNS, offering a differentiated therapeutic opportunity that has eluded development for over 20 years.

Risks and Challenges:

• Safety Monitoring: While preclinical data is robust, the management team acknowledges the need for long-term safety follow-up (via open-label extensions) to definitively rule out any delayed retinal or ocular toxicity for OV329.
• Clinical Translation: Success in Phase 1 (OV4071) must translate to clinical efficacy in the upcoming acute schizophrenia PoC study.
• Indication Selection: The decision to prioritize schizophrenia over epilepsy for the KCC2 program was driven by the overwhelming consistency of preclinical psychotropic data, requiring successful execution to validate the strategic pivot.
• Regulatory Hurdles: Ensuring the Phase 2 epilepsy study meets registrational requirements without the stigma of the parent compound's toxicity profile.

Management Commentary and Tone:

• Tone: Highly confident and enthusiastic; CEO Meg Alexander describes the timeframe as the "playoffs" and expresses strong conviction that the company will become the recognized leader in KCC2.
• Strategic Clarity: Management emphasizes a deliberate pipeline curation based on "differentiated mechanisms" and "small molecules" to address the lack of step-change improvements in neuro/psychiatry.
• Scientific Rigor: Highlights a "self-limiting" mechanism for KCC2 to address safety concerns and details extensive preclinical validation (>100 pharmacology studies) to support clinical advancement.

Analyst Questions and Answers:

• Q: Why prioritize schizophrenia over epilepsy for OV4071?
  • A: The preclinical data for antipsychotic effects is "undeniable" and "wildly consistent" across genetic and behavioral models, whereas the data for other indications is less robust; schizophrenia serves as a gateway to broader psychosis indications.
• Q: What constitutes a "positive" result from the ketamine challenge?
  • A: Positive results would confirm brain penetration, neuroactivity, and that electrophysiological biomarkers in humans match animal translational markers, providing early insights into predictive clinical efficacy.
• Q: How does OV329 avoid the retinal toxicity of Vigabatrin?
  • A: Differentiation is achieved by avoiding ocular partitioning (accumulation) and inhibiting the secondary enzyme Ornithine Aminotransferase (OAT), both of which are linked to the toxicity profile of the first-generation drug.
• Q: Is Phase 1 safety data sufficient for OV329's ocular safety?
  • A: Phase 1 shows a clean profile, but management is relying on the upcoming 12-week registrational Phase 2 study and long-term open-label extensions to build a comprehensive safety database for regulators.

Other Key Points:

• Mechanism Specifics: KCC2 acts as a "braking system" for the brain by pumping out chloride to enable GABA to function; over-activation is energetically impossible, ensuring a precise therapeutic window.
• Drug Properties: Both OV4071 and OV329 are oral small molecules designed for chronic use and ease of administration (no titration for OV329).
• Collaboration: Management noted no new partnership announcements were made during the call, focusing instead on internal catalysts and clinical execution.